Semaglutide and cardiovascular outcomes in people with type 2 diabetes

Step 1: understanding what the cardiovascular trials measured

The headline finding comes from the SUSTAIN-6 trial, a dedicated cardiovascular outcomes study in people with type 2 diabetes and high cardiovascular risk. Over roughly two years, those taking semaglutide had a lower rate of major adverse cardiovascular events (MACE) (a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke) compared with placebo. A subsequent, larger trial, SELECT (2023), extended the cardiovascular story to people with established cardiovascular disease who did not have diabetes, using the 2.4mg Wegovy dose. That is a different population and a different licence; it matters clinically because the mechanism of benefit is still being characterised.

The NICE appraisal of semaglutide for weight management, published as TA875, acknowledges cardiovascular risk reduction as a relevant outcome alongside weight loss. If you want to understand where semaglutide sits in UK treatment frameworks more broadly, the relationship between Wegovy and type 2 diabetes management is worth reading alongside this page.

Step 2: translating the evidence to an individual patient's situation

Clinical trial populations are carefully selected. SUSTAIN-6 enrolled people aged 50 or over with established cardiovascular disease, chronic kidney disease, or heart failure, alongside type 2 diabetes. If your background differs (lower CV risk, no diabetes, or different comorbidities) the trial findings do not translate directly to your situation. This is not a reason for pessimism; it is a reason to have the conversation with your GP or specialist rather than drawing conclusions from headlines.

One question our prescribers hear regularly is whether someone already on a GLP-1 medicine for weight management can count on cardiovascular protection as a secondary benefit. The honest answer is that the data are encouraging, but individual risk-benefit assessment is the only route to a clear answer. Our clinical team can discuss whether semaglutide is appropriate given your health history, but anyone with existing cardiovascular disease or type 2 diabetes should involve their GP or cardiologist in that decision.

There is also the question of which semaglutide product applies. Ozempic is licensed for type 2 diabetes; Wegovy is licensed for weight management. The cardiovascular risk-reduction wording in the UK sits within the Wegovy authorisation for a specific eligible group. These distinctions matter because they affect what a prescriber can and cannot appropriately prescribe. For more detail on the weight-management side of this, the Wegovy overview covers the licence clearly.

Step 3: safety considerations specific to this population

People managing type 2 diabetes alongside cardiovascular disease are often on multiple medicines. Semaglutide slows gastric emptying, which can affect the absorption timing of other oral drugs, including some diabetes medicines taken alongside it. That interaction profile needs a prescriber's eye, not a self-assessment. If you are currently taking metformin, SGLT2 inhibitors, or blood-pressure medicines, disclose all of them at consultation.

On the side-effect side, gastrointestinal effects (nausea being the most reported, followed by changes in bowel habit and occasional vomiting) are common, particularly in the first few weeks after starting or after a dose step up. These are not usually dangerous in otherwise healthy adults but can be more significant if you are managing cardiac conditions or taking diuretics, where dehydration risk rises. Seek medical attention promptly if gastrointestinal symptoms are severe or prolonged. The MHRA's Yellow Card scheme allows patients to report side effects directly.

Pregnancy, breastfeeding, and active attempts to conceive are clear contraindications; semaglutide is not recommended in any of these situations. If this applies to you, speak to your GP before starting or continuing treatment. More detail on reproductive considerations is on the semaglutide and pregnancy page.

Step 4: NHS access and the private route for this group

On the NHS, semaglutide for weight management (Wegovy) is accessed via specialist weight management services under TA875; waiting lists in many areas remain long. For cardiovascular risk reduction specifically, prescribing decisions sit with cardiologists and GPs managing the diabetes pathway, not with a weight-management service. These are different clinical streams and it is worth being clear with your GP which question you are asking.

A private consultation through a regulated online pharmacy is an option for people who want to explore weight-management treatment without waiting, provided they meet the licensed criteria and there are no contraindications. At nume, consultations are reviewed personally by a GPhC-registered Independent Prescriber, the same day you submit, Monday to Friday. Treatment for weight management, once approved, goes out the same afternoon by tracked DPD delivery, arriving the next working day. (If you are wondering about timing: orders placed by 12pm on a Friday still dispatch that day, so there is no need to wait until after a bank holiday to get started.)

If you have type 2 diabetes or a cardiovascular condition, a GP or specialist referral forms part of your clinical picture; our prescribers will ask about these during the assessment, and GP notification is standard at nume as part of our clinical process. A common question at this stage is whether semaglutide is appropriate for someone with type 2 diabetes, and separately, people managing type 1 alongside cardiovascular risk can find guidance on how semaglutide relates to type 1 diabetes before discussing their situation with a specialist. For a fuller picture of treatment options, the treatment overview is the right starting point, and you can read about Wegovy's cardiovascular authorisation in more detail on a dedicated page.